

Curriculum Vitae

Prof. Stephan Windecker

Office Address: Department of Cardiology
University Cardiovascular Center
Bern University Hospital, Inselspital
3010 Bern, Switzerland

Telephone: 41 - 31 - 632 44 97

FAX: 41 - 31 - 664 10 69

e-mail: stephan.windecker@insel.ch



PRESENT APPOINTMENT

2015- Chairman and Professor
Department of Cardiology, University Cardiovascular Center
Bern University Hospital, Inselspital, Bern, Switzerland

ACADEMIC RESPONSIBILITIES

2020 Vice-Dean, Faculty of Medicine, University of Bern, Switzerland
2020 Member, Clinical Study Group, Deutsches Zentrum für Herz-Kreislauf-Forschung, Germany

ACADEMIC DEGREES

1991 Doctor of Medicine (MD Degree)
University of Alabama at Birmingham, School of Medicine, USA
1992 Doctoral Thesis (Dr. med.), University of Heidelberg, Germany
2002 Privatdozent (PhD Equivalent), University of Bern, Switzerland
2006 Associate Professor of Cardiology, University of Bern, Switzerland
2010 (Extraordinary) Professor of Cardiology, University of Bern, Switzerland
2015 (Ordinary-Full) Professor of Cardiology, University of Bern, Switzerland

EDITORIAL BOARD ACTIVITIES

2010-2016 Associate Editor, Journal of the American College of Cardiology –
Cardiovascular Interventions
2017- Deputy Editor, Journal of the American College of Cardiology –
Cardiovascular Interventions
2012 Percutaneous Interventional Cardiovascular Medicine – The PCR-EAPCI
Textbook
2012- UpToDate - Section Editor, Interventional Cardiology

EUROPEAN SOCIETY OF CARDIOLOGY ACTIVITIES

2007-	Fellow of the European Society of Cardiology
2008-2012	Member of the ESC Press Committee, Editor of the ESC Congress News
2012-2014	Chairperson, ESC/EACTS Guidelines on Myocardial Revascularization
2013-2017	Chairperson, Task Force, Revision of the EU medical device advisory document on the evaluation of coronary stents (MEDDEV 2.7.1)
2014-2016	President of the European Association of Percutaneous Cardiovascular Interventions (EAPCI)
2016-2018	Chairman, ESC Clinical Practice Guideline Committee (1 st term)
2018-2020	Chairman, ESC Clinical Practice Guideline Committee (2 nd term)
2020-2022	Chair, ESC Congress Program Committee

RESEARCH INTERESTS

Clinical trials with focus on the evaluation of intracoronary devices and drugs for the treatment of coronary artery disease, antithrombotic therapy for patients requiring cardiac device implantation, and research related to minimal-invasive heart valve treatment including transcatheter aortic, mitral and tricuspid valve interventions.

SELECTED PUBLICATIONS

1. **Windecker S**, Remondino A, Eberli FR, Jüni P, Räber L, Wenaweser P, Togni M, Billinger M, Tüller D, Seiler C, Roffi M, Corti R, Sütsch G, Maier W, Lüscher T, Hess OM, Egger M, Meier B. Sirolimus-eluting and paclitaxel-eluting stents for coronary revascularization. *N Engl J Med* 2005;353:653-62
2. **Windecker S**, Serruys PW, Wandel S, Buszman P, Trznadel S, Linke A, Lenk K, Ischinger T, Klauss V, Eberli F, Corti R, Wijns W, Morice MC, di Mario C, Davies S, Eerdmans P, van Es GA, Meier B, Jüni P. Biolimus-Eluting Stent With Biodegradable Polymer Versus Sirolimus-Eluting Stent With Durable Polymer For Coronary Revascularisation: A Randomised Controlled Trial. *Lancet* 2008;372:1163-73
3. Serruys PW, Silber S, Garg S, van Geuns J, Richardt G, Buszman P, Kelbaek H, van Boven AJ, Hofma SH, Linke A, Klauss V, Wijns W, Macaya C, Garot P, DiMario C, Manoharan G, Kornowski R, Ischinger T, Bartorelli A, Ronden J, Bressers M, Gobbens P, Negoita M, van Leeuwen, **Windecker S**. Comparison of zotarolimus-eluting and everolimus-eluting coronary stents. *N Engl J Med* 2010;363:136-46
4. Meier B, Kalesan B, Mattle H, Khattab A, Hildick-Smith D, Dudek D, Andersen G, Ibrahim R, Schuler G, Walton A, Wahl A, **Windecker S**, Jüni P, for the PC Trial Investigators. Percutaneous closure of patent foramen ovale in cryptogenic embolism. *N Engl J Med* 2013;368:1083-91
5. Pilgrim T, Heg D, Roffi M, Tüller D, Muller O, Vuillomenet A, Cook S, Weilenmann D, Kaiser C, Jamshidi P, Fahrni T, Moschovitis A, Noble S, Eberli F, Wenaweser P, Jüni P, **Windecker S**. Ultrathin strut biodegradable polymer sirolimus-eluting stent versus durable polymer everolimus-eluting stent for percutaneous coronary revascularization (BIOSCIENCE): a randomized, single-blind, non-inferiority trial. *Lancet* 2014;384:2111-22
6. Siontis G, Stefanini G, Mavridis D, Siontis K, Alfonso F, Pérez-Vizcayno M, Byrne R, Kastrati A, Meier B, Salanti G, Jüni P, **Windecker S**. Percutaneous coronary interventional strategies for treatment of in-stent restenosis: a network meta-analysis. *Lancet* 2015;386:655-64
7. Vranckx P, Valgimigli M, Jüni P, Hamm C, Steg PG, Heg D, van Es GA, McFadden EP, Onuma Y, van Meijeren C, Chichareon P, Benit E, Möllmann H, Janssens L, Ferrario M, Moschovitis A, Zurakowski A, Dominici M, Van Geuns RJ, Huber K, Slagboom T, Serruys PW, **Windecker S**; GLOBAL LEADERS Investigators. Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed

- by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial. *Lancet*. 2018;392:940-949
8. Lanz J, Kim WK, Walther T, Burgdorf C, Möllmann H, Linke A, Redwood S, Thilo C, Hilker M, Joner M, Thiele H, Conzelmann L, Conradi L, Kerber S, Schymik G, Prendergast B, Husser O, Stortecky S, Heg D, Jüni P, **Windecker S**, Pilgrim T; SCOPE I investigators. Safety and efficacy of a self-expanding versus a balloon-expandable bioprosthesis for transcatheter aortic valve replacement in patients with symptomatic severe aortic stenosis: a randomised non-inferiority trial. *Lancet*. 2019;394:1619-1628.
 9. Piccolo R, Bona KH, Efthimiou O, Varenne O, Baldo A, Urban P, Kaiser C, Remkes W, Räber L, de Belder A, van 't Hof AWJ, Stankovic G, Lemos PA, Wilsgaard T, Reifart J, Rodriguez AE, Ribeiro EE, Serruys PWJC, Abizaid A, Sabaté M, Byrne RA, de la Torre Hernandez JM, Wijns W, Jüni P, **Windecker S**, Valgimigli M; Coronary Stent Trialists' Collaboration. Drug-eluting or bare-metal stents for percutaneous coronary intervention: a systematic review and individual patient data meta-analysis of randomised clinical trials. *Lancet*. 2019;393:2503-2510.
 10. Dangas GD, Tijssen JGP, Wöhrle J, Søndergaard L, Gilard M, Möllmann H, Makkar RR, Herrmann HC, Giustino G, Baldus S, De Backer O, Guimarães AHC, Gullestad L, Kini A, von Lewinski D, Mack M, Moreno R, Schäfer U, Seeger J, Tchétché D, Thomitzek K, Valgimigli M, Vranckx P, Welsh RC, Wildgoose P, Volkl AA, Zazula A, van Amsterdam RGM, Mehran R, **Windecker S**; GALILEO Investigators. A Controlled Trial of Rivaroxaban after Transcatheter Aortic-Valve Replacement. *N Engl J Med*. 2020; 9;382:120-129.
 11. De Backer O, Dangas GD, Jilaihawi H, Leipsic JA, Terkelsen CJ, Makkar R, Kini AS, Veien KT, Abdel-Wahab M, Kim WK, Balan P, Van Mieghem N, Mathiassen ON, Jeger RV, Arnold M, Mehran R, Guimarães AHC, Nørgaard BL, Kofoed KF, Blanke P, **Windecker S**, Søndergaard L; GALILEO-4D Investigators. Reduced Leaflet Motion after Transcatheter Aortic-Valve Replacement. *N Engl J Med*. 2020; 382:130-139.
 12. **Windecker S**, Latib A, Kedhi E, Kirtane AJ, Kandzari DE, Mehran R, Price MJ, Abizaid A, Simon DI, Worthley SG, Zaman A, Hudec M, Poliacikova P, Abdul Ghapar AKB, Selvaraj K, Petrov I, Mylotte D, Pinar E, Moreno R, Fabbicocchi F, Pasupati S, Kim HS, Aminian A, Tie C, Włodarczak A, Hur SH, Marx SO, Jankovic I, Brar S, Bousquette L, Liu M, Stone GW; ONYX ONE Investigators. Polymer-based or Polymer-free Stents in Patients at High Bleeding Risk. *N Engl J Med*, 2020;382:1208-1218.